SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells
RAS mutations are frequent in non-small cell lung cancer (NSCLC). However, targeting RAS or the downstream/upstream effectors, such as tyrosine kinase inhibitors (TKIs), has been proved to be difficult. Here, we found that the stemness of KRAS-mutant NSCLC cells but not the KRAS-wild type NSCLC cell...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-12-01
|
| Series: | Artificial Cells, Nanomedicine, and Biotechnology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21691401.2019.1646748 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839622711419076608 |
|---|---|
| author | Lei Jiang Weiping Xu Yi Chen Yue Zhang |
| author_facet | Lei Jiang Weiping Xu Yi Chen Yue Zhang |
| author_sort | Lei Jiang |
| collection | DOAJ |
| description | RAS mutations are frequent in non-small cell lung cancer (NSCLC). However, targeting RAS or the downstream/upstream effectors, such as tyrosine kinase inhibitors (TKIs), has been proved to be difficult. Here, we found that the stemness of KRAS-mutant NSCLC cells but not the KRAS-wild type NSCLC cells was promoted by TKIs treatment, as evident by the increase of ALDH1 activity, stemness marker expression and spheroid formation ability. Notably, SHP2 activation was found in KRAS-mutant NSCLC cells with TKIs treatment, as judged by the increase of tyrosine 542 phosphorylation (pSHP2 Y542), which activates the RAS/MEK/ERK pathway. On the contrary, inhibition of MEK was followed by a SHP2 activation in KRAS-mutant NSCLC cells. Additionally, inhibition of SHP2 attenuates the enhanced stemness of KRAS-mutant NSCLC cells induced by TKIs, characterized by decreasing ALDH1 activity, stemness marker expression and spheroid formation capacity, while had little effects on cell viability. Finally, we revealed that SHP2 inhibitor increased the sensitivity of TKIs and chemotherapy, which was potentiated by MEK inhibition. Our results suggest a possibility of using a combination of SHP2 inhibitor and TKIs for KRAS-mutant NSCLC treatment. |
| format | Article |
| id | doaj-art-7be1c6d38ef14ab3adf44b36b6449fff |
| institution | Matheson Library |
| issn | 2169-1401 2169-141X |
| language | English |
| publishDate | 2019-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Artificial Cells, Nanomedicine, and Biotechnology |
| spelling | doaj-art-7be1c6d38ef14ab3adf44b36b6449fff2025-07-21T21:16:25ZengTaylor & Francis GroupArtificial Cells, Nanomedicine, and Biotechnology2169-14012169-141X2019-12-014713231323810.1080/21691401.2019.1646748SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cellsLei Jiang0Weiping Xu1Yi Chen2Yue Zhang3Department of Pharmacy, Anhui No.2 Provincial People’s Hospital, Hefei, ChinaResearch Department, The First Affiliated Hospital of USTC, Hefei, ChinaDepartment of Pharmacy, Anhui No.2 Provincial People’s Hospital, Hefei, ChinaDepartment of Pharmacy, Anhui No.2 Provincial People’s Hospital, Hefei, ChinaRAS mutations are frequent in non-small cell lung cancer (NSCLC). However, targeting RAS or the downstream/upstream effectors, such as tyrosine kinase inhibitors (TKIs), has been proved to be difficult. Here, we found that the stemness of KRAS-mutant NSCLC cells but not the KRAS-wild type NSCLC cells was promoted by TKIs treatment, as evident by the increase of ALDH1 activity, stemness marker expression and spheroid formation ability. Notably, SHP2 activation was found in KRAS-mutant NSCLC cells with TKIs treatment, as judged by the increase of tyrosine 542 phosphorylation (pSHP2 Y542), which activates the RAS/MEK/ERK pathway. On the contrary, inhibition of MEK was followed by a SHP2 activation in KRAS-mutant NSCLC cells. Additionally, inhibition of SHP2 attenuates the enhanced stemness of KRAS-mutant NSCLC cells induced by TKIs, characterized by decreasing ALDH1 activity, stemness marker expression and spheroid formation capacity, while had little effects on cell viability. Finally, we revealed that SHP2 inhibitor increased the sensitivity of TKIs and chemotherapy, which was potentiated by MEK inhibition. Our results suggest a possibility of using a combination of SHP2 inhibitor and TKIs for KRAS-mutant NSCLC treatment.https://www.tandfonline.com/doi/10.1080/21691401.2019.1646748Non-small cell lung cancerSHP2KRASMEKstemness |
| spellingShingle | Lei Jiang Weiping Xu Yi Chen Yue Zhang SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells Artificial Cells, Nanomedicine, and Biotechnology Non-small cell lung cancer SHP2 KRAS MEK stemness |
| title | SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells |
| title_full | SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells |
| title_fullStr | SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells |
| title_full_unstemmed | SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells |
| title_short | SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells |
| title_sort | shp2 inhibitor specifically suppresses the stemness of kras mutant non small cell lung cancer cells |
| topic | Non-small cell lung cancer SHP2 KRAS MEK stemness |
| url | https://www.tandfonline.com/doi/10.1080/21691401.2019.1646748 |
| work_keys_str_mv | AT leijiang shp2inhibitorspecificallysuppressesthestemnessofkrasmutantnonsmallcelllungcancercells AT weipingxu shp2inhibitorspecificallysuppressesthestemnessofkrasmutantnonsmallcelllungcancercells AT yichen shp2inhibitorspecificallysuppressesthestemnessofkrasmutantnonsmallcelllungcancercells AT yuezhang shp2inhibitorspecificallysuppressesthestemnessofkrasmutantnonsmallcelllungcancercells |